Table 1.
Comparison of control and COPD participants from the CCELL study
| Control (N = 45) | COPD (N = 46) | P value | |
|---|---|---|---|
| Demographics | |||
| Age (years) | 62.6 (6.37) | 63.8 (6.64) | 0.39 |
| Males, n (%) | 28 (62%) | 29 (63%) | 1.00 |
| Anthropometrics | |||
| BMI (kg/m2) | 25.77 (2.63) | 25.32 (4.80) | 0.58 |
| SMI (kg/m2) | 7.49 (1.16) | 7.06 (1.57) | 0.15 |
| FFMI (kg/m2) | 16.39 (1.93) | 15.73 (2.71) | 0.19 |
| Pulmonary function | |||
| FEV1, % pred. | — | 48.33 (15.4) | — |
| FEV1/FVC | — | 0.46 (0.12) | — |
| GOLD stages | |||
| GOLD 2, n (%) | — | 18 (39%) | — |
| GOLD 3, n (%) | — | 25 (54%) | — |
| GOLD 4, n (%) | — | 3 (7%) | — |
| Muscle histology | |||
| Type I per cent | 35.5 ± 10.3 | 30.8 ± 16.9 | 0.12 |
| Type IIa per cent | 49.6 ± 7.6 | 56.0 ± 13.3 | 0.006* |
| Type IIx/IIax per cent | 14.9 ± 10.9 | 13.2 ± 12.0 | 0.47 |
| Type I CSA (μm2) | 4626 ± 1271 | 4928 ± 1840 | 0.36 |
| Type IIa CSA (μm2) | 4131 ± 1349 | 4627 ± 1615 | 0.12 |
| Type IIx/IIax CSA (μm2) | 3080 ± 1343 | 3473 ± 1541 | 0.28 |
Note: All data are presented as mean (standard deviation) unless otherwise noted.
Abbreviations: BMI, body mass index; CCELL, COPD Cachexia: Etiology of Low Lean muscle; COPD, chronic obstructive pulmonary disease; CSA, cross‐sectional area; FEV1, % pred., forced expired volume in 1 s, per cent of predicted value; FEV1/FVC, forced expiratory volume in 1 s‐to‐forced vital capacity ratio; FFMI, fat‐free mass index; GOLD, Global Initiative for Chronic Obstructive Lung Disease; SMI, skeletal muscle index.
*
Significant difference between groups.